Anti-glucuronoxylomannan IgG1 specific antibodies production in Cryptococcus neoformans resistant mice.
Keywords:
Cryptococcus neoformans, glucuronoxylomannan, cross-reactive antibodies, lgG subclasses.
Abstract
Background. Cryptococcus neoformans is a widely disseminated fungus shown to be responsible for infections in individuals with impaired cell mediated immunity, such as patients with human immunodeficiency virus (HIV). Cryptococcus neoformans has a polysaccharide capsule composed of glucuronoxylomannan (GXM), which acts as a major virulence factor and is considered to be a thymus independent type-2 antigen (TI-2).Objective. In the current study, the production kinetics were evaluated for IgG subclasses specific for GXM, and assessed with the cross reactive antibodies to Streptococcus pneumoniae polysaccharide. In addition, spleen B cell subpopulations were quantified in murine models of cryptococcosis with different susceptibilities to the infection.
Materials And Methods. Antibodies were detected by ELISA at different time intervals after C. neoformans infection in moderately resistant (Balb/c), highly resistant (CBA/j) and susceptible (C57BL/6) mouse strains. B cells subpopulations were determined by flow cytometry analysis.
Results. Early production of IgG1, described as protector antibodies, coincided with a decrease of the number of C. neoformans colony forming units in the lungs. Polysaccharide cross-reactive antibodies were detected in each of the three mouse strains. Antibody titers were highest in the susceptible strain (C57BL/6), a strain which also showed the highest proportion of splenic CD5+ B lymphocytes. In contrast, CBA/J mice showed the highest levels of CD43+ B.
Conclusions. These findings suggest that IgG1 antibodies specific for GXM, are implicated in host protection against C. neoformans infection and may be regulated by CD43+ cells. They also suggest that cross reactivity antibodies are not important in the protection against C. neoformans infection.
Downloads
Download data is not yet available.
How to Cite
1.
Parra C, González JM, Castañeda E, Fiorentino S. Anti-glucuronoxylomannan IgG1 specific antibodies production in Cryptococcus neoformans resistant mice. biomedica [Internet]. 2005 Mar. 1 [cited 2024 May 17];25(1):110-9. Available from: https://revistabiomedica.org/index.php/biomedica/article/view/1332
Some similar items:
- Patricia Escandón, Popchai Ngamskulrungroj, Wieland Meyer, Elizabeth Castañeda, In vitro mating of Colombian isolates of the Cryptococcus neoformans species complex , Biomedica: Vol. 27 No. 2 (2007)
- Jairo Lizarazo, Melva Linares, Catalina de Bedout, Ángela Restrepo, Clara Inés Agudelo, Elizabeth Castañeda, Grupo Colombiano para el Estudio de la Criptococosis, Results of nine years of the clinical and epidemiological survey on cryptococcosis in Colombia, 1997-2005 , Biomedica: Vol. 27 No. 1 (2007)
- Alexandra Castañeda, Sandra Huérfano, Maria Claudia Rodríguez, Elizabeth Castañeda, Recovery of Cryptococcus neoformans var. gattii serotype C from almond trees detritus , Biomedica: Vol. 21 No. 1 (2001)
- Alexandra Castañeda, Elizabeth Castañeda, lsolation of Cryptococcus species from Eucalyptus trees located in a park in Bogotá , Biomedica: Vol. 21 No. 1 (2001)
- Sunny Sánchez, Dolores Zambrano, Maylen García, César Bedoya, Carlos Fernández, María Teresa Illnait-Zaragozí, Molecular characterization of Cryptococcus neoformans isolates from HIV patients, Guayaquil, Ecuador , Biomedica: Vol. 37 No. 3 (2017)
- Efraín Guillermo Sánchez , David Acosta , Juan Álvarez, Gabriela Sánchez , Julio García-Casallas, Disseminated cryptococcosis by biological therapy: We must manage the risk , Biomedica: Vol. 42 No. 2 (2022)
- Isaura Torres, Juan E. Gallo , Oscar Mauricio Gómez , Álvaro Rúa-Giraldo , Juan G. McEwen , Ana María García , Gene expression profiles of ERG11, MDR1 and AFR1 in Cryptococcus neoformans var.grubbi from HIV patients , Biomedica: Vol. 42 No. 4 (2022)
Published
2005-03-01
Issue
Section
Original articles
Article metrics | |
---|---|
Abstract views | |
Galley vies | |
PDF Views | |
HTML views | |
Other views |